Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Graves’ disease: progress to date and future prospects

  • Chapter
Endocrine Autoimmunity and Associated Conditions

Part of the book series: Immunology and Medicine Series ((IMME,volume 27))

  • 83 Accesses

Abstract

The history of Graves’ disease can be characterized by four distinct eras: the first, beginning in the 1820s led to the clinical description of the disease by Parry (1825), Graves (1835) and von Basedow (1848). The second era, beginning in the 1940s, saw the introduction of therapeutic strategies using antithyroid drugs [1] and radioactive iodine [2] which were directed specifically at the thyroid and could both modify and cure the disease. The third era began in 1956 with the classic description by Adams and Purves [3] of a factor in the serum of patients with hyperthyroid Graves’ disease which stimulated thyroid function; the so called long acting thyroid stimulator (LATS). The fourth and final era, which brings us to the present time began with the cloning of the thyrotropin (TSH) receptor by Vassart and his colleagues in 1989 [4; Chapter 2]. As a result of these crucial observations and the intervening contributions of many other clinicians and scientists we understand far better the clinical disease and its pathogenesis [5,6].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Astwood EB. Treatment of hyperthyroidism with thiourea and thiouracil. J Am Med Assoc. 1943;122:78–89.

    CAS  Google Scholar 

  2. Chapman EM. History of the discovery and early use of radioactive iodine. J Am Med Assoc. 1983;250:2042–2051.

    CAS  Google Scholar 

  3. Adams DD, Purves HD. Abnormal responses in the assay of thyrotropin. Proceedings of the University of Otago Medical School. 1956;34:11–12.

    Google Scholar 

  4. Parmentier M, Libert F, Maenhaut C et al. Molecular cloning of the thyrotropin receptor. Science. 1989;246:1620–1622.

    PubMed  CAS  Google Scholar 

  5. Weetman AP, McGregor AM. Autoimmune thyroid disease: developments in our understanding. Endocr Rev. 1984;5:309–355.

    PubMed  CAS  Google Scholar 

  6. Weetman AP, McGregor AM. Autoimmune thyroid disease: further developments in our understanding. Endocr Rev. 1994;15:788–830.

    PubMed  CAS  Google Scholar 

  7. Rees Smith B, McLachlan S M, Furmaniak J. Autoantibodies to the thyrotropin receptor. Endocr Rev. 1988;9:106–121.

    PubMed  CAS  Google Scholar 

  8. Nagayama Y, Kaufman KD, Seto P, Rapoport B. Molecular cloning, sequence and functional expression of the cDNA for the human thyrotropin receptor. Biochem Biophys Res Commun. 1989;165:1184–1190.

    PubMed  CAS  Google Scholar 

  9. McGregor AM. Graves’ disease and the thyrotropin (TSH) receptor. In: Edwards CRW, Lincoln DW, eds. Recent Advances in Endocrinology and Metabolism. Churchill Livingstone 1992;4:51–65.

    Google Scholar 

  10. Vanderpump MPJ, Tunbridge WM. The epidemiology of thyroid diseases. In: Braverman LE, Utiger RD, eds. Werner and Ingbars The Thyroid. Lippincott-Raven: Philadelphia; 1996:474–482.

    Google Scholar 

  11. Mangklabruks A, Cox N, De Groot LJ. Genetic factors in autoimmune thyroid disease analysed by restriction fragment length polymorphisms of candidate genes. J Clin Endocrinol Metab. 1991;73:236–244.

    PubMed  CAS  Google Scholar 

  12. Abraham LJ, French MAH, Dawkins RL. Polymorphic MHC ancestral haplotypes affect the activity of tumour necrosis factor-alpha. Clin Exp Immunol. 1993;92:14–18.

    PubMed  CAS  Google Scholar 

  13. Yanagawa T, Mangklabruks A, Chang Y-B et al. Human histocompatibility leucocyte antigen-DQA 1*0501 allele associated with genetic susceptibility to Graves’ disease in a Caucasian population. J Clin Endocrinol Metab. 1993;76:1569–1574.

    PubMed  CAS  Google Scholar 

  14. Chuang L-M, Wu HP, Chang CC et al. HAL DRB1/DQA1/DQB1 haplotype determines thyroid autoimmunity in patients with insulin dependent diabetes mellitus. Clin Endocrinol. 1996;45:631–636.

    CAS  Google Scholar 

  15. Yanagawa T, Mangklabruks A, De Groot LJ. Strong association between HLA-DQA1 *0501 and Graves’ disease in a male Caucasian population. J Clin Endocrinol Metab. 1994;79:227–229.

    PubMed  CAS  Google Scholar 

  16. Cuddihy RM, Bahn RS. Lack of an independent association between the human leukocyte antigen allele DQA1*0501 and Graves’ disease. J Clin Endocrinol Metab. 1996;81:847–849.

    PubMed  CAS  Google Scholar 

  17. Inoue D, Sato K, Sugawa H et al. Apparent genetic difference between hypothyroid patients with blocking-type thyrotropin receptor antibody and those without, as shown by restriction fragment length polymorphism analyses of HLA-D loci. J Clin Endocrinol Metab. 1993;77:606–610.

    PubMed  CAS  Google Scholar 

  18. Cho BY, Chung JH, Shong YK et al. A strong association between thyrotropin receptor-blocking antibody — positive atrophic autoimmune thyroiditis and HLA-B8 and HLA-DQB1*0302 in Koreans. J Clin Endocrinol Metab. 1993;77:611–615.

    PubMed  CAS  Google Scholar 

  19. Tamai H, Kimura A, Dong R-P et al. Resistance to autoimmune thyroid disease is associated with HLA-DQ. J Clin Endocrinol Metab. 1994;78:94–97.

    PubMed  CAS  Google Scholar 

  20. Roman SH, Greenberg D, Rubinstein P, Wallenstein S, Davies TF. Genetics of autoimmune thyroid disease: lack of evidence for linkage to HLA within families. J Clin Endocrinol Metab. 1992;74:496–503.

    PubMed  CAS  Google Scholar 

  21. Shields DC, Ratanachaiyavong S, McGregor AM, Collins A, Morton NE. Combined segregation and linkage analysis of Graves’ disease with a thyroid autoantibody diathesis. Am J Hum Genet. 1994;55:540–554.

    PubMed  CAS  Google Scholar 

  22. Blakemore AIF, Watson PF, Weetman AP et al. Association of Graves’ disease with an allele of the Interleukin-1 receptor antagonist gene. J Clin Endocrinol Metab. 1995;80:111–115.

    PubMed  CAS  Google Scholar 

  23. Yanagawa T, Hidaka Y, Guimaraes V, Soliman M, De Groot LJ. CTLA-4 gene polymorphism associated with Graves’ disease in a Caucasian population. J Clin Endocrinol Metab. 1995;80:41–45.

    PubMed  CAS  Google Scholar 

  24. Donner H, Rau H, Walfish PG et al. CTLA4 alanine-17 confers genetic susceptibility to Graves’ disease and to type I diabetes mellitus. J Clin Endocrinol Metab. 1997;82:143–146.

    PubMed  CAS  Google Scholar 

  25. Kotsa KD, Watson PF, Weetman AP. No association between a thyrotropin receptor gene polymorphism and Graves’ disease in the female population. Thyroid. 1997;7:31–33.

    PubMed  CAS  Google Scholar 

  26. De Roux N, Shields DC, Misrahi M, Ratanachaiyavong S, McGregor AM, Milgrom E. Analysis of the thyrotropin receptor as a candidate gene in familial Graves’ disease. J Clin Endocrinol Metab. 1996;81:3483–3486.

    PubMed  Google Scholar 

  27. Ahmed AS, Young PR, Penhaie WJ. The effects of female sex hormones on the development of autoimmune thyroiditis in thymectomised and irradiated rats. Clin Exp Immunol. 1983;4:351–358.

    Google Scholar 

  28. Takasu N. Komiya I, Nagasawa Y, Aaswa T, Yamada T. Exacerbation of autoimmune thyroid dysfunction after unilateral adrenalectomy in patients with Cushing’s syndrome due to an adrenocortical adenoma. N Engl J Med. 1990;322:1708–1712.

    PubMed  CAS  Google Scholar 

  29. Bottazzo GF, Pujol-Borrell R, Hanafusa T, Feldmann M. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet. 1983;2:1115–1119.

    PubMed  CAS  Google Scholar 

  30. Hassman R, Solic N, Jasani B, Hall R, McGregor AM. Immunological events leading to destructive thyroiditis in the AUG rat. Clin Exp Immunol. 1988;73:410–416.

    PubMed  CAS  Google Scholar 

  31. Hamilton F, Black M, Farquharson MA, Stewart C, Foulis AK. Spatial correlation between thyroid epithelial cells expressing class II MHC molecules and interferon-gamma-containing lymphocytes in human autoimmune thyroid disease. Clin Exp Immunol. 1991;83:64–68.

    PubMed  CAS  Google Scholar 

  32. Brown TR, Sundick RS, Dhar A, Sheth D, Bagchi N. Uptake and metabolism of iodine is crucial for the development of thyroiditis in obese strain chickens. J Clin Invest. 1991;88:106–111.

    PubMed  CAS  Google Scholar 

  33. Schuppert F, Taniguchi S-I, Schroder S, Dralle H, von Zur Muhlen A, Kohn LD. In vivo and in vitro evidence for iodide regulation of MHC class I and class II expression in Graves’ disease. J Clin Endocrinol Metab. 1996;81:3622–3628.

    PubMed  CAS  Google Scholar 

  34. Gorman CA. A critical review of the role of stress in hyperthyroidism. In: Drexhage HA, de Vijlder JJM and Wiersinga WM, eds. The Thyroid Gland Environment and Autoimmunity. Amsterdam: Elsevier Science Publishers; 1990:191–200.

    Google Scholar 

  35. Winsa B, Adami H, Bergstrom R et al. Stressful life events and Graves’ disease. Lancet. 1991;338:1475–1479.

    PubMed  CAS  Google Scholar 

  36. Tomer Y, Davies TF. Infection, thyroid disease, and autoimmunity. Endocr Rev. 1993;14:107–115.

    PubMed  CAS  Google Scholar 

  37. Hidaka Y, Amino N, Iwatani Y, Itoh E, Matsunaga M, Tamaki H. Recurrence of thyrotoxicosis after attack of allergic rhinitis in patients with Graves’ disease. J Clin Endocrinol Metab. 1993;77:1667–1660.

    PubMed  CAS  Google Scholar 

  38. Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumours. Ann Intern Med. 1991;115:178–183.

    PubMed  CAS  Google Scholar 

  39. Van Liessum PA, De Mulder PHM, Mattijssen EJM, Corstens FHM, Wagener DJT. Hypothyroidism and goitre during interleukin-2 therapy without LAK cells. Lancet. 1989;1:224.

    PubMed  Google Scholar 

  40. Hoekman K, von Blomberg-Van Der Flier BME, Wagstaff J, Drexhage HA, Pinedo HM. Reverible thyroid dysfunction during treatment with GM-CSF. Lancet. 1991;338:541–542.

    PubMed  CAS  Google Scholar 

  41. Tandon N, Freeman MA, Weetman AP. T cell responses to synthetic TSH receptor peptides in Graves’ disease. Clin Exp Immunol. 1992;89:468–473.

    PubMed  CAS  Google Scholar 

  42. Soliman M, Kaplan E, Yanagawa T, Hidaka Y, Fisfalen M, De Groot LJ. T cells recognise multiple epitopes in the human thyrotropin receptor extracellular domain. J Clin Endocrinol Metab. 1995;80:905–914.

    PubMed  CAS  Google Scholar 

  43. Dayan CM, Londei M, Corcoran AE et al. Autoantigen recognition by thyroid-infiltrating T cells in Graves’ disease. Proc Natl Acad Sci USA. 1991;88:7415–7419.

    PubMed  CAS  Google Scholar 

  44. Soliman M, Kaplan E, Guimaraes V, Yanagawa T, de Groot LJ. T cell recognition of residue 158–176 in TSH receptor confers risk for development of thyroid autoimmunity in siblings in a familty with Graves’ disease. Thyroid. 1996;6:545–561.

    PubMed  CAS  Google Scholar 

  45. Sercarz EE, Lehmann PV, Ametani A et al. Dominance and crypticity of T cell antigenic determinants. Ann Rev Immunol. 1993;11:729–766.

    CAS  Google Scholar 

  46. Davies TF, Martin A, Concepcion ES, Graves P, Cohen I, Ben-Nun A. Evidence of limited variability of antigen receptors on intrathyroidal T cells in autoimmune thyroid disease. N Engl J Med. 1991;325:238–244.

    PubMed  CAS  Google Scholar 

  47. Davies TF, Martin A, Concepcion ES et al. Evidence for selective accumulation of intrathyroidal T lymphocytes in human autoimmune thyroid disease based on T cell receptor V gene usage. J Clin Invest. 1992;89:157–162.

    PubMed  CAS  Google Scholar 

  48. Mcintosh RS, Tandon N, Pickerill AP, Davies R, Barnett D, Weetman AP. IL-2 receptor-positive intrathyroidal lymphocytes in Graves’ disease: analysis of Va transcript microheterogeneity. J Immunol. 1993;91:3884–3893.

    Google Scholar 

  49. Caso-Pelaez E, McGregor AM, Banga JP A polyclonal T cell repertoire of V-alpha and V-beta T cell receptor gene families in intrathyroidal T lymphocytes of Graves’ disease patients. Scand J Immunol. 1995;41:141–147.

    PubMed  CAS  Google Scholar 

  50. Heufelder AE, Wenzel BE, Scriba PC. Antigen receptor variable region repertoires expressed by T cells infiltrating thyroid retroorbital and pretibial tissue in Graves’ disease. J Clin Endocrinol Metab. 1996;81:3733–3739.

    PubMed  CAS  Google Scholar 

  51. Sugihara S, Fujiwara H, Niimi H, Shearer GM. Self-thyroid epithelial cell (TEC)-reactive CD8+ T cell lines/clones derived from autoimmune thyroiditis lesions. J Immunol. 1995;155:1619–1628.

    PubMed  CAS  Google Scholar 

  52. Watson PF, Pickerill P, Davies R, Weetman AP. Analysis of cytokine gene expression in Graves’ disease and multinodular goitre. J Clin Endocrinol Metab. 1994;79:355–360.

    PubMed  CAS  Google Scholar 

  53. Nishikawa T, Yamashita S, Namba H et al. Interferon-gamma inhibition of human thyrotropin receptor gene expression. J Clin Endocrinol Metab. 1993;77:1084–1089.

    PubMed  CAS  Google Scholar 

  54. Giordano C, Stassi G, de Maria R et al. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto’s thyroiditis. Science. 1997;275:960–963.

    PubMed  CAS  Google Scholar 

  55. Nakashima M, Martin A, Davies TF. Intrathyroidal T cell accumulation in Graves’ disease:delineation of mechanisms based on in situ T cell receptor analysis. J Clin Endocrinol Metab. 1996;81:3346–3351.

    PubMed  CAS  Google Scholar 

  56. McKenzie JM. The bioassay of thyrotropin in serum. Endocrinology. 1958;63:372–382.

    PubMed  CAS  Google Scholar 

  57. McKenzie JM. Delayed thyroid response to serum from thyrotoxic patients. Endocrinology. 1958;63:865–868.

    Google Scholar 

  58. Kriss JP, Pleshakov V, Chien JR. Isolation and identification of the long-acting thyroid stimulator and its relation to hyperthyroidism and circumscribed pretibial myxoedema. J Clin Endocrinol Metab. 1964;24:1005–1028.

    PubMed  CAS  Google Scholar 

  59. McKenzie JM. Neonatal Graves’ disease. J Clin Endocrinol Metab. 1964;24:660–668.

    PubMed  CAS  Google Scholar 

  60. Adams DD, Kennedy TH. Occurrence in thyrotoxicosis of a gamma globulin which protects LATS from neutralisation by an extract of thyroid gland. J Clin Endocrinol Metab. 1967;27:173–177.

    PubMed  CAS  Google Scholar 

  61. Mehdi SQ, Nussey SS. A radio-ligand receptor assay for the long-acting thyroid stimulator. Biochem J. 1975;145:105–111.

    PubMed  CAS  Google Scholar 

  62. Smith BR, Hall R. Thyroid-stimulating immunoglobulins in Graves’ disease. Lancet. 1974;2:427–430.

    PubMed  CAS  Google Scholar 

  63. Southgate K, Creagh FM, Teece M, Kingswood C, Rees Smith B. A receptor assay for the measurement of TSH receptor antibodies in unextracted serum. Clin Endocrinol. 1984;20:539–548.

    CAS  Google Scholar 

  64. Adams DD, Fastier FN, Howie JB, Kennedy TH, Kilpatrick JA, Stewart RDH. Stimulation of the human thyroid by infusions of plasma containing LATS protector. J Clin Endocrinol Metab. 1974;39:826.

    PubMed  CAS  Google Scholar 

  65. Ambesi-Impiombato FS, Parks LAM, Coon HG. Culture of hormone-dependent epithelial cells from rat thyroids. Proc Natl Acad Sci USA. 1980;77:3455–3459.

    PubMed  CAS  Google Scholar 

  66. Vitti P, Rotella CM, Valente WA et al. Characterisation of the optimal stimulatory effects of Graves’ monoclonal and serum immunoglobulin G on adenosine 3’5’-monophosphate production in FRTL5 thyroid cells. A potential clinical assay. J Clin Endocrinol Metab. 1983;57:782–791.

    PubMed  CAS  Google Scholar 

  67. Matsuura N, Yamada Y, Nohara Y et al. Familial neonatal transient hypothyroidism due to maternal TSH-binding inhibitor immunoglobulins. N Eng J Med. 1980;303:738–741.

    CAS  Google Scholar 

  68. Hinds WE, Takai N, Rapoport B, Filetti S, Clark OH. Thyroid-stimulating immunoglobulin bioassay using cultured human thyroid cells. J Clin Endocrinol Metab. 1981;52:1204–1210.

    PubMed  CAS  Google Scholar 

  69. Rapoport B, Greenspan FS, Filetti S, Pepitone M. Clinical experience with a human thyroid cell bioassay for thyroid stimulating immunoglobulin. J Clin Endocrinol Metab. 1984;58:332–338.

    PubMed  CAS  Google Scholar 

  70. Kasagi K, Konishi J, Iida Y et al. A new in vitro assay for human thyroid stimulator using cultured thyroid cells: effect of sodium chloride on adenosine 3′5′-monophosphate increase. J Clin Endocrinol Metab. 1982;54:108–114.

    PubMed  CAS  Google Scholar 

  71. Konishi J, Iida Y, Endo K et al. Inhibition of thyrotropin-induced adenosine 3’5’-monophosphate increase by immunoglobulins from patients with primary myxoedema. J Clin Endocrinol Metab. 1983;57:544–549.

    PubMed  CAS  Google Scholar 

  72. Zakarija MJ. Immunochemical characterisation of the thyroid-stimulating antibody (TSAb) of Graves’ disease: evidence for restricted heterogeneity. J Clin Lab Immunol. 1983;10:77.

    PubMed  CAS  Google Scholar 

  73. Weetman AP, Yateman ME, Ealey PA et al. Thyroid-stimulating antibody activity between different immunoglobulin G subclasses. J Clin Invest. 1990;86:723.

    PubMed  CAS  Google Scholar 

  74. Libert F, Lefort A, Gerard C et al. Cloning, sequencing and expression of the human thyrotropin (TSH) receptor: evidence for binding of autoantibodies. Biochem Biophys Res Commun. 1989;165:1250–1255.

    PubMed  CAS  Google Scholar 

  75. Nagayama Y, Rapoport B. The thyrotropin receptor 25 years after its discovery: new insights after its molecular cloning. Mol Endocrinol. 1992;6:145–156.

    PubMed  CAS  Google Scholar 

  76. Perret J, Ludgate M, Libert F et al. Stable expression of the human TSH receptor in CHO cells and characterisation of differentially expressing clones. Biochem Biophys Res Commun. 1990;171:1044–1050.

    PubMed  CAS  Google Scholar 

  77. Weetman AP, McGregor AM, Wheeler MH, Hall R. Extrathyroidal sites of autoantibody synthesis in Graves’ disease. Clin Exp Immunol. 1984;56:330–336.

    PubMed  CAS  Google Scholar 

  78. Cho BY, Shong YK, Lee HK, Koh C-S, Min HK. Graves’ hyperthyroidism following primary hypothyroidism: sequential changes in various activities of thyrotropin receptor antibodies. Acta Endocrinol (Copenh.) 1989;120:447–450.

    CAS  Google Scholar 

  79. Chiovato L, Vitti P, Santini F et al. Incidence of antibodies blocking thyrotropin effect in vitro in patients with euthyroid or hypothyroid autoimmune thyroiditis. J Clin Endocrinol Metab. 1990;71:40–45.

    PubMed  CAS  Google Scholar 

  80. Chazenbalk GD, Nagayama Y, Russo D, Wadsworth HL, Rapoport B. Functional analysis of the cytoplasmic domains of the human thyrotropin receptor by site-directed mutagenesis. J Biol Chem. 1990;265:20970–20975.

    PubMed  CAS  Google Scholar 

  81. Russo D, Chazenbalk GD, Nagayama Y, Wadsworth HL, Rapoport B. Site-directed mutagenesis of the human thyrotropin receptor: Role of asparagine-linked oligosaccharides in the expression of a functional receptor. Mol Endocrinol. 1991;5:29–33.

    PubMed  CAS  Google Scholar 

  82. Nagayama Y, Wadsworth HL, Chazenbalk GD, Russo D, Seto P, Rapoport B. Thyrotropinluteinizing hormone/chorionic gonadotropin receptor extracellular domain chimeras as probes for thyrotropin receptor function. Proc Natl Acad Sci USA. 1991:88:902–905.

    PubMed  CAS  Google Scholar 

  83. Wadsworth HL, Russo D, Nagayama Y, Chazenbalk GD, Rapoport B. Studies on the role of amino acids 38–45 in the expression of a functional thyrotropin receptor. Mol Endocrinol. 1992;6:394–398.

    PubMed  CAS  Google Scholar 

  84. Nagayama Y, Rapoport B. Thyroid stimulatory autoantibodies in different patients with autoimmune thyroid disease do not all recognise the same components of the human thyrotropin receptor: Selective role of receptor amino acids Ser 25-Glu 30. J Clin Endocrinol Metab. 1992;75:1425–1430.

    PubMed  CAS  Google Scholar 

  85. Costagliola S, Swillens S, Niccoli P, Dumont JE, Vassart G, Ludgate M. Binding assay for thyrotropin receptor autoantibodies using the recombinant receptor protein. J Clin Endocrinol Metab. 1992;75:1540–1544.

    PubMed  CAS  Google Scholar 

  86. Kosugi S, Ban T, Akamizu T, Valente W, Kohn LD. Use of thyrotropin receptor (TSHR) mutants to detect stimulating TSHR antibodies in hypothyroid patients with idiopathic myxoedema, who have blocking TSHR antibodies. J Clin Endocrinol Metab. 1993;77:19–24.

    PubMed  CAS  Google Scholar 

  87. Graves PN, Vlase H, Davies TF. Folding of the recombinant human TSH receptor extracellular domain: identification of folded monomeric and tetrameric complexes that bind TSH receptor autoantibodies. Endocrinology. 1995;136:521–527.

    PubMed  CAS  Google Scholar 

  88. Rapoport B, McLachlan SM, Kakinuma A, Chazenbalk GD. Critical relationship between autoantibody recognition and TSH receptor maturation as reflected in the acquisition of complex carbohyrdrate. J Clin Endocrinol Metab. 1996;81:2525–2533.

    PubMed  CAS  Google Scholar 

  89. Park JY, Kim IJ, Lee MH et al. Identification of the peptides that inhibit the stimulation of TSH receptor by Graves’ immunoglobulin G from peptide libraries. Endocrinology. 1997;138:617–626.

    PubMed  CAS  Google Scholar 

  90. Tonacchera M, Van Sande J, Parma J, Duprez L. TSH receptor and disease. Clin Endocrinol. 1996;44:621–633.

    CAS  Google Scholar 

  91. Vanderpump MPJ, Ahlquist JAO, Franklyn JA, Clayton RN. Consensus statement for good practice and audit measures in the management of hypothyroidism and hyperthyroidism. Br Med J. 1996;313:539–544.

    CAS  Google Scholar 

  92. Wartofsky L, Glinoer D, Solomon B et al. Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan and the United States. Thyroid. 1991;1:129–135.

    PubMed  CAS  Google Scholar 

  93. McGregor AM, Petersen MM, McLachlan SM, Rooke P, Rees Smith B, Hall R. Carbimazole and the autoimmune response in Graves’ disease. N Engl J Med. 1980;303;302–307.

    PubMed  CAS  Google Scholar 

  94. Ratanachaiyavong S, McGregor AM. Immunosuppressive effects of antithyroid drugs. Clin Endocrinol Metab. 1985;14:449–466.

    PubMed  CAS  Google Scholar 

  95. Hashizume K, Ichikawa K, Sakurai A et al. Administration of thyroxine in treated Graves’ disease: effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med. 1991;324:947–953.

    PubMed  CAS  Google Scholar 

  96. Tamai H, Hayaki I, Kawai K et al. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves’ disease patients. J Clin Endocrinol Metab. 1995;80:1481–1484.

    PubMed  CAS  Google Scholar 

  97. Mclver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A. Lack of effect of thyroxine in patients with Graves’ hyperthyroidism who are treated with an antithyroid drug. N Engl J Med. 1996;334:220–224.

    Google Scholar 

  98. Rittmaster RS, Zwicker H, Abbott EC et al. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of TSH receptor antibodies in patients with Graves’ disease. J Clin Endocrinol Metab. 1996;81:3283–3288.

    PubMed  CAS  Google Scholar 

  99. Benker G, Vitti P, Kahaly G, Raue F, Tegler F, Hirche H, Reinwein D and European Mutlicenter Study Group. Response to methimazole in Graves’ disease. Clin Endocrinol. 1995;43:257–263.

    CAS  Google Scholar 

  100. Solomon B, Evaul JE, Burman KD, Wartofsky L. Remission rates with antithyroid drug therapy: continuing influence of iodine intake? Ann Int Med. 1987;107:510–512.

    PubMed  CAS  Google Scholar 

  101. Weetman AP, Pickerill AP, Watson P, Chatterjee VK, Edwards OM. Treatment of Graves’ disease with the block-replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse. Q J Med. 1994;87:337–341.

    PubMed  CAS  Google Scholar 

  102. Wilson R, Buchanan L, Fraser WD, McKillop JH, Thomson JA. Do higher doses of Carbimazole improve remission in Graves’ disease? Q J Med. 1996;89:381–385.

    Google Scholar 

  103. Kim WB, Cho BY, Park HY et al. Epitopes for thyroid-stimulating antibodies in Graves’ sera: A possible link of heterogeneity to differences in response to antithyroid drug treatment. J Clin Endocrinol Metab. 1996;81:1758–1767.

    PubMed  CAS  Google Scholar 

  104. Huang GC, Page MJ, Nicholson LB, Collison KS, McGregor AM, Banga JP. The thyrotropin hormone receptor of Graves’ disease:overexpression of the extracellular domain in insect cells using recombinant baculovirus, immunoaffinity purification and analysis of autoantibody binding. J Mol Endocrinol. 1993;10:127–142.

    PubMed  CAS  Google Scholar 

  105. Nicholson LB, Vlase H, Graves P et al. Monoclonal antibodies to the human TSH receptor:epitope mapping and binding to the native receptor on the basolateral plasma membrane of thyroid follicular cells. J Mol Endocrinol. 1996;16:159–170.

    PubMed  Google Scholar 

  106. Rapoport B, Portolano S, McLachlan SM. Combinatorial librariesmew insights into human organ-specific autoantibodies. Immunol Today. 1995;16:43–49.

    PubMed  CAS  Google Scholar 

  107. Morgenthaler NG, Kim MR, Tremble J et al. Human immunoglobulin G autoantibodies from EB virus-transformed B lymphocytes: characterisation by immune precipitation with recombinant antigen and biological activity. J Clin Endocrinol Metab. 1996;81:3155–3161.

    PubMed  CAS  Google Scholar 

  108. Watanabe Y, Tahara K, Hirai A, Tada H, Kohn LD, Amino N. Subtypes of anti-TSH receptor antibodies classified by various assays using CHO cells expressing wild type or chimeric human TSH receptor. Thyroid. 1997;7:13–19.

    PubMed  CAS  Google Scholar 

  109. Morgenthaler NG, Tremble J, Huang GC, Scherbaum WA, McGregor AM, Banga JP. Binding of antithyrotropin receptor autoantibodies in Graves’ disease serum to nascent, in vitro translated TSH receptor: ability to map epitopes recognised by antibodies. J Clin Endocrinol Metab. 1996;81:700–706.

    PubMed  CAS  Google Scholar 

  110. Jaume JC, Kakinuma A, Chazenbalk GD, Rapoport B, McLachlan SM. Thyrotropin receptor autoantibodies in serum are present at much lower levels than thyroid peroxidase autoantibodies: analysis by flow cytometry. J Clin Endocrinol Metab. 1997;82:500–507.

    PubMed  CAS  Google Scholar 

  111. Shimojo N, Kohno Y, Yamaguchi K-I et al. Induction of Graves’-like disease in mice by immunisation with fibroblasts transfected with the TSH receptor and a class II molecule. Proc Natl Acad Sci USA. 1996;93:11074–11079.

    PubMed  CAS  Google Scholar 

  112. Weiner HL. Oral tolerance for the treatment of autoimmune disease. Ann Rev Med. 1997;48:341–351.

    PubMed  CAS  Google Scholar 

  113. Guimaraes VC, Quintans J, Fisfalen M et al. Suppression of development of experimental autoimmune thyroiditis by oral administration of thyroglobulin. Endocrinology. 1995;136:3353–3359.

    PubMed  CAS  Google Scholar 

  114. Guimaraes VC, Quintans J, Fisfalen M-E et al. Immunosuppression of thyroiditis. Endocrinology. 1996;137:2199–2207.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, King’s College School of Medicine and Dentistry, Bessemer Road, London, SE5 9PJ, UK

    A. M. McGregor & J.-P. Banga

Authors
  1. A. M. McGregor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J.-P. Banga
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medicine Clinical Sciences Centre, University of Sheffield Northern General Hospital, Sheffield, S5 7AU, UK

    A. P. Weetman

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

McGregor, A.M., Banga, JP. (1998). Graves’ disease: progress to date and future prospects. In: Weetman, A.P. (eds) Endocrine Autoimmunity and Associated Conditions. Immunology and Medicine Series, vol 27. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5044-6_4

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-5044-6_4

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6118-6

  • Online ISBN: 978-94-011-5044-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation